June is National Cancer Survivors Month

Listen to “June is National Cancer Survivors Month” on Spreaker.

HOW A PATIENT’S OWN BLOOD CELLS CAN HELP ATTACK CANCER CELLS

During National Cancer Survivors Month, people around the country are recognizing the more than 16.9 million cancer survivors in the U.S. who are living with, through, and beyond their disease. www.lls.org

One of the most innovative treatments giving hope to people with blood cancers such as lymphoma, leukemia or myelomas is CAR T-cell therapy.1
• CAR T-cell therapies are made from a patient’s own blood cells and use the immune system to identify and attack cancer cells.2
• These innovative treatments have shown to be potentially life-saving therapies for patients with certain blood cancers, like large B-cell lymphoma (LBCL), which is the most common form of non-Hodgkin lymphoma and can be aggressive.2,3
• However, awareness of CAR T-cell therapy among potentially eligible patients in the U.S. is low – only about 1 out of 5 are aware of the therapy as a treatment option.4

Michael, a small business owner and father of three girls living in New Jersey, was diagnosed with LBCL in October 2018 and was treated with chemotherapy which he described as “pretty aggressive.” His cancer quickly returned – only four months later – and he decided to participate in a clinical trial for CAR T-cell therapy. Today he is 3+ years cancer-free.

Dr. Lori Leslie, a hematologist and oncologist at Hackensack Meridian John Theurer Cancer Center in New Jersey, treats people with blood cancers and has seen firsthand their devastating impact particularly for those whose cancer returns. Dr. Leslie, who treated Michael with CAR T-cell therapy, is available to discuss how recent treatment advances like CAR T-cell therapies offer people like Michael hope.

Michael and Dr. Leslie speak about CAR T-cell therapies for cancers like LBCL and how eligible patients and caregivers can learn more about these innovative treatments.

Interview is courtesy: Kite, a Gilead Company

1Siegel RL, Miller KD, Fuchs HE. Cancer statistics, 2022. CA Cancer J Clin. 2022;70:7-33.
2Zhao L, Cao YK. Engineered T cell therapy for cancer in the clinic. Front Immunol. 2019;10:1-20.
3National Cancer Institute. Cancer stat facts: Non-Hodgkin lymphoma. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed May 10, 2022.
4 Data on File.

#michael #drlorileslie #car #t-cell #therapy #cancer #lbcl #patients #caregivers #innovativetreatments #kitegileadcompany #bloodcells #cancersurvivors #lls #b-cell